Skip to main content
Erschienen in: European Radiology 11/2015

01.11.2015 | Breast

Correlation between 18F-FDG uptake on PET/CT and prognostic factors in triple-negative breast cancer

verfasst von: Hye Ryoung Koo, Jeong Seon Park, Keon Wook Kang, Wonshik Han, In Ae Park, Woo Kyung Moon

Erschienen in: European Radiology | Ausgabe 11/2015

Einloggen, um Zugang zu erhalten

Abstract

Objectives

The purpose of this study was to investigate whether a correlation exists between 18F-fluorodeoxyglucose (FDG) uptake and prognostic factors in triple-negative breast cancer (TNBC).

Methods

Between January 2009 and December 2013, 103 patients (mean age, 50.6 years) with primary TNBC (mean, 2.6 cm; range, 1.0–6.5 cm) underwent 18F-FDG PET/CT for initial staging. Correlations between maximum standardized uptake value (SUVmax) on PET/CT and prognostic factors including tumour size, nodal status, histological grade, Ki-67 proliferation index, tumour suppressor p53, and ‘basal-like’ markers (epidermal growth factor receptor and CK 5/6) were assessed.

Results

The mean SUVmax of the 103 tumours was 10.94 ± 5.25 (range: 2–32.8). There was a positive correlation between SUVmax and Ki-67 (Spearman’s rho = 0.29, P = 0.003) and tumour size (Spearman’s rho = 0.27, P = 0.006), whereas this relationship was not observed in the nodal status, histological grade, p53 status and ‘basal-like’ phenotypes. In a multivariate regression analysis, Ki-67 (P < 0.001) and tumour size (P = 0.009) were significantly associated with SUVmax in TNBCs.

Conclusions

Increased 18F-FDG uptake on PET/CT was correlated with a high Ki-67 proliferation index and larger tumour size in TNBC. These results suggest a potential role of 18F-FDG PET/CT in identifying TNBC with more aggressive behaviour.

Key points

A wide range of FDG uptake reflected heterogeneity of cancer metabolism.
FDG uptake was correlated with the Ki-67 proliferation index in TNBC.
FDG uptake was correlated with tumour size in TNBC.
FDG uptake was not correlated withbasal-likephenotype.
Literatur
1.
Zurück zum Zitat Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109:1721–1728CrossRefPubMed Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109:1721–1728CrossRefPubMed
2.
Zurück zum Zitat Dent R, Trudeau M, Pritchard KI et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429–4434CrossRefPubMed Dent R, Trudeau M, Pritchard KI et al (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 13:4429–4434CrossRefPubMed
3.
Zurück zum Zitat Hudis CA, Gianni L (2011) Triple-negative breast cancer: an unmet medical need. Oncologist 16:1–11CrossRefPubMed Hudis CA, Gianni L (2011) Triple-negative breast cancer: an unmet medical need. Oncologist 16:1–11CrossRefPubMed
4.
Zurück zum Zitat Lehmann BD, Pietenpol JA (2014) Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol 232:142–150PubMedCentralCrossRefPubMed Lehmann BD, Pietenpol JA (2014) Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol 232:142–150PubMedCentralCrossRefPubMed
5.
Zurück zum Zitat Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO (2007) Prognostic markers in triple-negative breast cancer. Cancer 109:25–32CrossRefPubMed Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO (2007) Prognostic markers in triple-negative breast cancer. Cancer 109:25–32CrossRefPubMed
6.
Zurück zum Zitat Prat A, Adamo B, Cheang MC, Anders CK, Carey LA, Perou CM (2013) Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist 18:123–133PubMedCentralCrossRefPubMed Prat A, Adamo B, Cheang MC, Anders CK, Carey LA, Perou CM (2013) Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist 18:123–133PubMedCentralCrossRefPubMed
7.
Zurück zum Zitat Koolen BB, Vrancken Peeters MJ, Aukema TS et al (2012) 18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques. Breast Cancer Res Treat 131:117–126CrossRefPubMed Koolen BB, Vrancken Peeters MJ, Aukema TS et al (2012) 18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques. Breast Cancer Res Treat 131:117–126CrossRefPubMed
8.
Zurück zum Zitat Aukema TS, Rutgers EJ, Vogel WV et al (2010) The role of FDG PET/CT in patients with locoregional breast cancer recurrence: a comparison to conventional imaging techniques. Eur J Surg Oncol 36:387–392CrossRefPubMed Aukema TS, Rutgers EJ, Vogel WV et al (2010) The role of FDG PET/CT in patients with locoregional breast cancer recurrence: a comparison to conventional imaging techniques. Eur J Surg Oncol 36:387–392CrossRefPubMed
9.
Zurück zum Zitat Hatt M, Groheux D, Martineau A et al (2013) Comparison between 18F-FDG PET image-derived indices for early prediction of response to neoadjuvant chemotherapy in breast cancer. J Nucl Med 54:341–349CrossRefPubMed Hatt M, Groheux D, Martineau A et al (2013) Comparison between 18F-FDG PET image-derived indices for early prediction of response to neoadjuvant chemotherapy in breast cancer. J Nucl Med 54:341–349CrossRefPubMed
10.
Zurück zum Zitat Groheux D, Giacchetti S, Moretti JL et al (2011) Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging 38:426–435CrossRefPubMed Groheux D, Giacchetti S, Moretti JL et al (2011) Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging 38:426–435CrossRefPubMed
11.
Zurück zum Zitat Basu S, Chen W, Tchou J et al (2008) Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer 112:995–1000CrossRefPubMed Basu S, Chen W, Tchou J et al (2008) Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer 112:995–1000CrossRefPubMed
12.
Zurück zum Zitat Tchou J, Sonnad SS, Bergey MR et al (2010) Degree of tumor FDG uptake correlates with proliferation index in triple negative breast cancer. Mol Imaging Biol 12:657–662CrossRefPubMed Tchou J, Sonnad SS, Bergey MR et al (2010) Degree of tumor FDG uptake correlates with proliferation index in triple negative breast cancer. Mol Imaging Biol 12:657–662CrossRefPubMed
13.
Zurück zum Zitat Koo HR, Park JS, Kang KW et al (2014) 18F-FDG uptake in breast cancer correlates with immunohistochemically defined subtypes. Eur Radiol 24:610–618CrossRefPubMed Koo HR, Park JS, Kang KW et al (2014) 18F-FDG uptake in breast cancer correlates with immunohistochemically defined subtypes. Eur Radiol 24:610–618CrossRefPubMed
14.
Zurück zum Zitat Groheux D, Hindie E, Giacchetti S et al (2012) Triple-negative breast cancer: early assessment with 18F-FDG PET/CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathologic complete response and are at a high risk of early relapse. J Nucl Med 53:249–254CrossRefPubMed Groheux D, Hindie E, Giacchetti S et al (2012) Triple-negative breast cancer: early assessment with 18F-FDG PET/CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathologic complete response and are at a high risk of early relapse. J Nucl Med 53:249–254CrossRefPubMed
15.
Zurück zum Zitat Ohara M, Shigematsu H, Tsutani Y et al (2013) Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer: usefulness for malignant grade of triple-negative breast cancer. Breast 22:958–963CrossRefPubMed Ohara M, Shigematsu H, Tsutani Y et al (2013) Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer: usefulness for malignant grade of triple-negative breast cancer. Breast 22:958–963CrossRefPubMed
16.
Zurück zum Zitat Mountz JM, Yankeelov TE, Rubin DL et al (2014) Letter to cancer center directors: progress in quantitative imaging as a means to predict and/or measure tumor response in cancer therapy trials. J Clin Oncol 32:2115–2116CrossRefPubMed Mountz JM, Yankeelov TE, Rubin DL et al (2014) Letter to cancer center directors: progress in quantitative imaging as a means to predict and/or measure tumor response in cancer therapy trials. J Clin Oncol 32:2115–2116CrossRefPubMed
17.
Zurück zum Zitat Mankoff DA, Pryma DA, Clark AS (2014) Molecular imaging biomarkers for oncology clinical trials. J Nucl Med 55:525–528CrossRefPubMed Mankoff DA, Pryma DA, Clark AS (2014) Molecular imaging biomarkers for oncology clinical trials. J Nucl Med 55:525–528CrossRefPubMed
18.
Zurück zum Zitat Hammond ME, Hayes DF, Dowsett M et al (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784–2795PubMedCentralCrossRefPubMed Hammond ME, Hayes DF, Dowsett M et al (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784–2795PubMedCentralCrossRefPubMed
19.
Zurück zum Zitat Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118–145CrossRefPubMed Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118–145CrossRefPubMed
20.
Zurück zum Zitat Zabaglo L, Salter J, Anderson H et al (2010) Comparative validation of the SP6 antibody to Ki67 in breast cancer. J Clin Pathol 63:800–804CrossRefPubMed Zabaglo L, Salter J, Anderson H et al (2010) Comparative validation of the SP6 antibody to Ki67 in breast cancer. J Clin Pathol 63:800–804CrossRefPubMed
21.
Zurück zum Zitat Zellars RC, Hilsenbeck SG, Clark GM et al (2000) Prognostic value of p53 for local failure in mastectomy-treated breast cancer patients. J Clin Oncol 18:1906–1913PubMed Zellars RC, Hilsenbeck SG, Clark GM et al (2000) Prognostic value of p53 for local failure in mastectomy-treated breast cancer patients. J Clin Oncol 18:1906–1913PubMed
22.
Zurück zum Zitat Nielsen TO, Hsu FD, Jensen K et al (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10:5367–5374CrossRefPubMed Nielsen TO, Hsu FD, Jensen K et al (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10:5367–5374CrossRefPubMed
23.
Zurück zum Zitat Cheang MC, Voduc D, Bajdik C et al (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14:1368–1376CrossRefPubMed Cheang MC, Voduc D, Bajdik C et al (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14:1368–1376CrossRefPubMed
24.
Zurück zum Zitat Gerdes J, Li L, Schlueter C et al (1991) Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 138:867–873PubMedCentralPubMed Gerdes J, Li L, Schlueter C et al (1991) Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 138:867–873PubMedCentralPubMed
25.
Zurück zum Zitat Inwald EC, Klinkhammer-Schalke M, Hofstadter F et al (2013) Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat 139:539–552PubMedCentralCrossRefPubMed Inwald EC, Klinkhammer-Schalke M, Hofstadter F et al (2013) Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat 139:539–552PubMedCentralCrossRefPubMed
26.
Zurück zum Zitat Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ (2011) Strategies for subtypes: dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22:1736–1747PubMedCentralCrossRefPubMed Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ (2011) Strategies for subtypes: dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22:1736–1747PubMedCentralCrossRefPubMed
27.
Zurück zum Zitat Keam B, Im SA, Lee KH et al (2011) Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res 13:R22PubMedCentralCrossRefPubMed Keam B, Im SA, Lee KH et al (2011) Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res 13:R22PubMedCentralCrossRefPubMed
28.
Zurück zum Zitat Zhang G, Xie W, Liu Z et al (2014) Prognostic function of Ki-67 for pathological complete response rate of neoadjuvant chemotherapy in triple-negative breast cancer. Tumori 100:136–142PubMed Zhang G, Xie W, Liu Z et al (2014) Prognostic function of Ki-67 for pathological complete response rate of neoadjuvant chemotherapy in triple-negative breast cancer. Tumori 100:136–142PubMed
29.
Zurück zum Zitat Urruticoechea A, Smith IE, Dowsett M (2005) Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 23:7212–7220CrossRefPubMed Urruticoechea A, Smith IE, Dowsett M (2005) Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 23:7212–7220CrossRefPubMed
31.
Zurück zum Zitat Lehmann BD, Bauer JA, Chen X et al (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Investig 121:2750–2767PubMedCentralCrossRefPubMed Lehmann BD, Bauer JA, Chen X et al (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Investig 121:2750–2767PubMedCentralCrossRefPubMed
32.
Zurück zum Zitat Kim S, Kim do H, Jung WH, Koo JS (2013) Metabolic phenotypes in triple-negative breast cancer. Tumour Biol 34:1699–1712CrossRefPubMed Kim S, Kim do H, Jung WH, Koo JS (2013) Metabolic phenotypes in triple-negative breast cancer. Tumour Biol 34:1699–1712CrossRefPubMed
33.
Zurück zum Zitat Uematsu T, Kasami M, Yuen S (2009) Comparison of FDG PET and MRI for evaluating the tumor extent of breast cancer and the impact of FDG PET on the systemic staging and prognosis of patients who are candidates for breast-conserving therapy. Breast Cancer 16:97–104CrossRefPubMed Uematsu T, Kasami M, Yuen S (2009) Comparison of FDG PET and MRI for evaluating the tumor extent of breast cancer and the impact of FDG PET on the systemic staging and prognosis of patients who are candidates for breast-conserving therapy. Breast Cancer 16:97–104CrossRefPubMed
34.
Zurück zum Zitat Kim JY, Lee SH, Kim S, Kang T, Bae YT (2015) Tumour 18F-FDG Uptake on preoperative PET/CT may predict axillary lymph node metastasis in ER-positive/HER2-negative and HER2-positive breast cancer subtypes. Eur Radiol 25:1172–1181CrossRefPubMed Kim JY, Lee SH, Kim S, Kang T, Bae YT (2015) Tumour 18F-FDG Uptake on preoperative PET/CT may predict axillary lymph node metastasis in ER-positive/HER2-negative and HER2-positive breast cancer subtypes. Eur Radiol 25:1172–1181CrossRefPubMed
35.
Zurück zum Zitat Gil-Rendo A, Martinez-Regueira F, Zornoza G, Garcia-Velloso MJ, Beorlegui C, Rodriguez-Spiteri N (2009) Association between [18F]fluorodeoxyglucose uptake and prognostic parameters in breast cancer. Br J Surg 96:166–170CrossRefPubMed Gil-Rendo A, Martinez-Regueira F, Zornoza G, Garcia-Velloso MJ, Beorlegui C, Rodriguez-Spiteri N (2009) Association between [18F]fluorodeoxyglucose uptake and prognostic parameters in breast cancer. Br J Surg 96:166–170CrossRefPubMed
36.
Zurück zum Zitat Buck A, Schirrmeister H, Kuhn T et al (2002) FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging 29:1317–1323CrossRefPubMed Buck A, Schirrmeister H, Kuhn T et al (2002) FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging 29:1317–1323CrossRefPubMed
37.
Zurück zum Zitat Silwal-Pandit L, Vollan HK, Chin SF et al (2014) TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance. Clin Cancer Res 20:3569–3580CrossRefPubMed Silwal-Pandit L, Vollan HK, Chin SF et al (2014) TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance. Clin Cancer Res 20:3569–3580CrossRefPubMed
38.
Zurück zum Zitat Soussan M, Orlhac F, Boubaya M et al (2014) Relationship between tumor heterogeneity measured on FDG-PET/CT and pathological prognostic factors in invasive breast cancer. PLoS One 9:e94017PubMedCentralCrossRefPubMed Soussan M, Orlhac F, Boubaya M et al (2014) Relationship between tumor heterogeneity measured on FDG-PET/CT and pathological prognostic factors in invasive breast cancer. PLoS One 9:e94017PubMedCentralCrossRefPubMed
Metadaten
Titel
Correlation between 18F-FDG uptake on PET/CT and prognostic factors in triple-negative breast cancer
verfasst von
Hye Ryoung Koo
Jeong Seon Park
Keon Wook Kang
Wonshik Han
In Ae Park
Woo Kyung Moon
Publikationsdatum
01.11.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
European Radiology / Ausgabe 11/2015
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-015-3734-z

Weitere Artikel der Ausgabe 11/2015

European Radiology 11/2015 Zur Ausgabe

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Klinikreform soll zehntausende Menschenleben retten

15.05.2024 Klinik aktuell Nachrichten

Gesundheitsminister Lauterbach hat die vom Bundeskabinett beschlossene Klinikreform verteidigt. Kritik an den Plänen kommt vom Marburger Bund. Und in den Ländern wird über den Gang zum Vermittlungsausschuss spekuliert.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.